Bromide

Bromide

SCHEMBL468140

Br.CCc1csc(-c2cc(CCN)ccc2[N+](=O)[O-])n1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.37
KAT2B Q92831 2/20 0.36
AOC3 Q16853 1/20 0.36
BACE1 P56817 2/20 0.35
RAB9A P51151 5/20 0.35
NPC1 O15118 3/20 0.35
POLB P06746 2/20 0.35
GAA P10253 2/20 0.35
EIF4E P06730 4/20 0.33
TAAR1 Q96RJ0 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
LMNA P02545 3/20 0.32
RECQL P46063 1/20 0.32
THRB P10828 1/20 0.32
ALDH1A1 P00352 1/20 0.32
NFKB1 P19838 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204921 0.79 EIF4E (0.43) MAPTMEN1KMT2AKDM4ERAB9A
SCHEMBL6414960 0.79 MEN1 (0.41) MAPTMEN1KMT2AKDM4EBACE1
SCHEMBL996247 0.75 TSHR (0.45) MAPTMEN1KMT2AKDM4EKAT2B
SCHEMBL995982 0.69 EIF4E (0.43) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL27835698 0.67 GAA (0.44) MAPTRAB9AGAAEIF4ESMN1; SMN2
SCHEMBL23413210 0.66 TDP1 (0.56) MAPTKDM4EGAATAAR1LMNA
SCHEMBL29780553 0.66 TDP1 (0.56) MAPTKDM4EGAATAAR1LMNA
SCHEMBL9820329 0.66 TDP1 (0.61) MAPTMEN1KMT2AKDM4EPOLB
SCHEMBL12643165 0.65 TAAR1 (0.56) MAPTTAAR1SMN1; SMN2LMNAALDH1A1
SCHEMBL1467508 0.65 MAPK1 (0.56) MAPTMEN1KMT2AKDM4EBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2967066-A1 COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES Aerpio Therapeutics Inc. (US) 2016-01-20 EP disclosed
WO-2014145068-A1 COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES AERPIO THERAPEUTICS INC. (US) 2014-09-18 WO disclosed
EP-2624916-A2 COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES Aerpio Therapeutics Inc. (US) 2013-08-14 EP disclosed
EP-2451279-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS Akebia Therapeutics Inc. (US) 2012-05-16 EP disclosed
WO-2012047966-A2 COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES AKEBIA THERAPEUTICS INC. (US) 2012-04-12 WO disclosed
EP-2385763-A1 METHODS FOR TREATING VASCULAR LEAK SYNDROME Akebia Therapeutics Inc. (US) 2011-11-16 EP disclosed
US-20110253725-A1 MULTI-PORT BEVERAGE AND FOOD CONTAINERS KILLIAN WILLIAM 2011-10-20 US disclosed
WO-2011005330-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS AKEBIA THERAPEUTICS INC. (US) 2011-01-13 WO disclosed
WO-2010081172-A1 METHODS FOR TREATING VASCULAR LEAK SYNDROME AKEBIA THERAPEUTICS INC. (US) 2010-07-15 WO disclosed